INT115463

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2004
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 13
Total Number 16
Disease Relevance 8.47
Pain Relevance 1.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plau) extracellular space (Plau) extracellular region (Plau)
kinase activity (Plau)
Anatomy Link Frequency
plasma 3
plaque 1
lung 1
MDA-MB-231 1
Plau (Mus musculus)
Pain Link Frequency Relevance Heat
metalloproteinase 42 99.76 Very High Very High Very High
Inflammation 308 92.76 High High
Analgesic 8 92.00 High High
chemokine 22 86.40 High High
cytokine 74 84.56 Quite High
cINOD 36 79.20 Quite High
COX-2 inhibitor 6 78.84 Quite High
fibrosis 9 76.40 Quite High
Central nervous system 1 66.04 Quite High
Kinase C 13 61.04 Quite High
Disease Link Frequency Relevance Heat
Metastasis 63 99.76 Very High Very High Very High
Pulmonary Disease 88 99.46 Very High Very High Very High
Breast Cancer 119 99.32 Very High Very High Very High
Nicotine Addiction 4 97.44 Very High Very High Very High
Cancer 491 97.16 Very High Very High Very High
INFLAMMATION 321 92.76 High High
Glioblastoma 13 91.92 High High
Pulmonary Emphysema 5 88.44 High High
Parkinson's Disease 1 85.04 High High
Emphysema 7 84.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We previously observed that uPA and PAI-1 are concentrated in NAF compared to plasma [22].
Positive_regulation (concentrated) of uPA in plasma
1) Confidence 0.47 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.27 Pain Relevance 0.04
On the other hand, evaluating the circulating level of celecoxib demonstrated the effect of the agent, and consistent with preclinical reports discussed above, NAF levels of PAI-1 and PGE2 decreased in relation to increasing celecoxib concentrations, while uPA plasma levels increased in relation to increased circulating celecoxib (Figure 1).


Positive_regulation (increased) of uPA in plasma
2) Confidence 0.44 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.41 Pain Relevance 0
uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer

Background

Positive_regulation (upregulated) of uPA associated with breast cancer
3) Confidence 0.44 Published 2008 Journal BMC Cancer Section Title Doc Link PMC2580770 Disease Relevance 0.42 Pain Relevance 0
While increased urokinase-type plasminogen activator (uPA) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that uPA overexpression may suppress tumor growth and prolong survival.
Positive_regulation (increased) of urokinase-type plasminogen activator associated with cancer and breast cancer
4) Confidence 0.44 Published 2008 Journal BMC Cancer Section Abstract Doc Link PMC2580770 Disease Relevance 0.41 Pain Relevance 0
These findings are consistent with animal studies which suggest that, unlike in subjects with invasive breast cancer (in whom high levels of uPA are associated with a poor prognosis [24]), in high risk women the upregulation of uPA (in association with downregulation of PAI-1 and PGE2) may have a breast cancer chemopreventive effect.


Positive_regulation (upregulation) of uPA associated with breast cancer
5) Confidence 0.44 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.27 Pain Relevance 0.16
PAI-1 and PGE2 decreased in NAF and uPA increased in plasma in relation to the circulating level of celecoxib, which may better reflect the action of the agent than dosage, since individuals metabolize celecoxib at different rates.
Positive_regulation (increased) of uPA in plasma
6) Confidence 0.38 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.25 Pain Relevance 0
The highly invasive breast cancer cell line, MDA-MB-231, which has increased constitutive levels of uPA, is due to impairment in the ARE-mediated decay of uPA mRNA; this is correlated with HuR overexpression and p38 MAP kinase induction [113].
Positive_regulation (increased) of uPA in MDA-MB-231 associated with breast cancer
7) Confidence 0.12 Published 2010 Journal Cell Mol Life Sci Section Body Doc Link PMC2921490 Disease Relevance 1.15 Pain Relevance 0.03
Proteases involved in these processes include serine proteases (the plasminogen activators uPA and tPA), matrix metalloproteinases (MMPs), and cysteine proteases (cathepsins B, D, L and H) [12].
Positive_regulation (activators) of uPA associated with metalloproteinase
8) Confidence 0.08 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2904700 Disease Relevance 1.43 Pain Relevance 0.21
The increased activity of uPA and its receptor has been associated with invasiveness in a number of tumors [26].
Positive_regulation (increased) of uPA associated with cancer
9) Confidence 0.08 Published 2010 Journal Cell Mol Life Sci Section Body Doc Link PMC2921490 Disease Relevance 1.86 Pain Relevance 0.50
Also multiple MAPKs including JNK appear to play a role in the upregulation of the urokinase-like plasminogen activator (U-PA) promoter in PC 3 cells [73].
Positive_regulation (upregulation) of U-PA
10) Confidence 0.07 Published 2004 Journal Cell Commun Signal Section Body Doc Link PMC449737 Disease Relevance 0.52 Pain Relevance 0.06
Since then, additional studies have confirmed increased levels of NE in lung samples from COPD patients and demonstrated elevated levels of CG, PR3, uPA, and MMPs -1, -2, -8, -9, and -14 in various lung samples from smokers and COPD patients when compared with healthy subjects (Damiano et al 1986; Reilly and Chapman Jr 1988; Abboud et al 1998; Betsuyaku et al 1996; Finlay et al 1997; Betsuyaku et al 1999; Hill et al 1999; Betsuyaku et al 2000b; Cataldo et al 2000; Imai et al 2001; Beeh et al 2003; Kang et al 2003).
Spec (may) Positive_regulation (elevated) of uPA in lung associated with nicotine addiction, pulmonary disease and metalloproteinase
11) Confidence 0.05 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2629972 Disease Relevance 1.17 Pain Relevance 0.18
Increased plasma levels of u-PA were associated with plaque rupture (3.0 +/- 0.7 vs 2.5 +/- 0.9 ng/mL, P =.062).
Positive_regulation (Increased) of u-PA in plaque
12) Confidence 0.02 Published 2004 Journal Am. Heart J. Section Body Doc Link 14691435 Disease Relevance 0 Pain Relevance 0
Pro-u-PA and plasminogen were incubated with the indicated concentrations of POGG and MOGG in the presence of Spectrozyme UK to determine reciprocal activation of pro-u-PA.
Positive_regulation (activation) of pro-u-PA
13) Confidence 0.01 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0.06 Pain Relevance 0.09
S. fulvellum was selected by a screening of approximately 700 of plant extracts for compounds that enhance reciprocal activation of pro-u-PA and plasminogen.
Positive_regulation (activation) of pro-u-PA
14) Confidence 0.01 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0.15 Pain Relevance 0.10
The fibrinolytic activities of compound 1 and 2 were investigated by the reciprocal activation of single chain urokinase-type plasminogen activator (pro-u-PA) and plasminogen.
Spec (investigated) Positive_regulation (activation) of pro-u-PA
15) Confidence 0.01 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0 Pain Relevance 0
According to our knowledge, this is the first time to isolate MOGG from marine lives and discover that POGG and MOGG enhanced reciprocal activation of pro-u-PA and plasminogen in vitro.

4.

Positive_regulation (activation) of pro-u-PA
16) Confidence 0.01 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707035 Disease Relevance 0.09 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox